FindTrial
Sign In

A Comparative Study of Oliceridine versus Alfentanil and Sufentanil in Clinical Application for Painless Gastrointestinal Endoscopy

A Comparative Study of Oliceridine versus Alfentanil and Sufentanil in Clinical Application for Painless Gastrointestinal Endoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113483
Enrollment
Unknown
Registered
2025-11-28
Start date
2025-12-10
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastrointestinal endoscopy

Interventions

Oliceridine Group: Oliceridine in combination with remimazolam and ciprofol
Alfentanil Group:Alfentanil in combination with remimazolam and ciprofol
Sufentanil Group:Sufentanil in combination with remimazolam and ciprofol

Sponsors

Qingdao Binhai University Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 to 65 years; Either sex; BMI <= 30 kg/m^2;Patients with an ASA classification of I to II;Patients scheduled for gastrointestinal endoscopy.

Exclusion criteria

Exclusion criteria: Known allergy to any component of the study medications;Abnormal airway anatomy;Significant comorbidities or severe systemic diseases;History of substance abuse;Scheduled for complex endoscopic therapeutic procedures.

Design outcomes

Primary

MeasureTime frame
Respiratory depression;—

Secondary

MeasureTime frame
Drug dosage;Awakening time;Quality of life scores at 24 hours postoperatively;Anesthesia-related score;—

Countries

China

Contacts

Public ContactZuolei Chen

Qingdao Binhai University Affiliated Hospital

qyfymzk@163.com+86 185 6196 7939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026